Review in Stroke, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland (A.S.G.).ORCID 0000-0001-9109-0811
Sana M Al-KhatibDivision of Cardiology and Duke Clinical Research Institute, Duke University, Durham, NC (S.M.A.-K., R.D.L., K.L.T.).ORCID 0000-0002-3561-0146
Patrice Desvigne-NickensDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.D.-N., L.S.C.).ORCID 0000-0003-1073-641X
Nisha BansalDivision of Nephrology, University of Washington, Seattle (N.B.).ORCID 0000-0002-9583-8628
Cheryl D BushnellDepartment of Neurology, Wake Forest University, Winston-Salem, NC (C.D.B.).ORCID 0000-0002-3162-7610
Margaret C FangDivision of Hospital Medicine, University of California, San Francisco (M.C.F.).ORCID 0000-0003-3362-1543
James V FreemanDepartment of Medicine, Yale University, New Haven, CT (J.V.F.).ORCID 0000-0002-4614-6879
Brian F GageDepartment of Medicine, Washington University, St Louis, MO (B.F.G.).ORCID 0000-0002-4727-8742
Thorsten HankeDepartment of Cardiac Surgery, Asklepios Klinikum Harburg-Hamburg, Germany (T.H.).
Elaine M HylekDepartment of Medicine, Boston University, MA (E.M.H.).
Renato D LopesDivision of Cardiology and Duke Clinical Research Institute, Duke University, Durham, NC (S.M.A.-K., R.D.L., K.L.T.).ORCID 0000-0003-2999-4961
Peter A NoseworthyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (P.A.N.).ORCID 0000-0002-4308-0456
Vivek Y ReddyDepartment of Medicine, Icahn School of Medicine, New York, NY (V.Y.R.).ORCID 0000-0002-5638-4993
Daniel E SingerDivision of General Internal Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston (D.E.S.).ORCID 0000-0001-6145-4848
Kevin L ThomasDivision of Cardiology and Duke Clinical Research Institute, Duke University, Durham, NC (S.M.A.-K., R.D.L., K.L.T.).ORCID 0000-0002-0040-5396
Mellanie True HillsStopAfib.org, American Foundation for Women's Health, Decatur, TX (M.T.H.).ORCID 0000-0001-8298-4418
Mintu P TurakhiaVeterans Affairs Palo Alto Health Care System, CA (M.P.T.).ORCID 0000-0001-8025-0904
Susan J ZiemanDivision of Geriatrics and Clinical Gerontology, National Institute on Aging, National Institutes of Health, Bethesda, MD (S.J.Z.).
Lawton S CooperDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.D.-N., L.S.C.).ORCID 0000-0002-9704-8777
Emelia J BenjaminCardiovascular Medicine, Department of Medicine, Boston Medical Center, Boston University School of Medicine, MA (E.J.B.).ORCID 0000-0003-4076-2336
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HDR01DK095024 · NIDDK · STANFORD UNIVERSITY · PI WINKELMAYER, WOLFGANG CHRISTOPH · 2012 to 2023
$4.3M
PRROPS: Pathways of Risk and Resilience for Overlapping Pain and SensitizationR01NS121419 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Emelia J. Benjamin, ROBERT R EDWARDS · 2021 to 2026
$3.7M
Optimizing Atrial Fibrillation Management in CKDR01HL142834 · NHLBI · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA, GO, ALAN S · 2019 to 2022
$3.4M
CAPSITE: Community Assessment of Pain and Sensitization in the ElderlyR01AG066010 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., EDWARDS, ROBERT R · 2020 to 2025
$3.3M
Pain in community-based older African American Adults: The Jackson Heart StudyR01AG066914 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., EDWARDS, ROBERT R · 2020 to 2024
$3.2M
Shared decision making for stroke prevention in atrial fibrillation (SDM4Afib)R01HL131535 · NHLBI · MAYO CLINIC ROCHESTER · PI MONTORI, VICTOR MANUEL · 2016 to 2020
$3.2M
AFGen Consortium: Atrial Fibrillation Genomics to Functional AnalysesR01HL128914 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2015 to 2018
$3.1M
Safety and Effectiveness of Left Atrial Appendage Closure in Atrial Fibrillation (SAFELY-AF)R01HL142765 · NHLBI · YALE UNIVERSITY · PI FREEMAN, JAMES · 2019 to 2022
$2.9M
Optimizing stroke prevention for older adults with atrial fibrillation: Towards rigorous evaluation and judicious application of a new deviceR01AG062436 · NIA · MAYO CLINIC ROCHESTER · PI NOSEWORTHY, PETER A, YAO, XIAOXI · 2020 to 2024
$2.5M
FHS-NEXT - Framingham Novel EXam using TechnologyR01HL141434 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., MCMANUS, DAVID D. · 2019 to 2022
Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular disease, the number of individuals affected by AF will continue increasing over time. While multiple proven stroke prevention therapies exist, important questions remain about the optimal approach to stroke prevention at the population and individual patient levels. Our report summarizes the National Heart, Lung, and Blood Institute virtual workshop focused on identifying key research opportunities related to stroke prevention in AF. The workshop reviewed major knowledge gaps and identified targeted research opportunities to advance stroke prevention in AF in the following areas: (1) improving risk stratification tools for stroke and intracranial hemorrhage; (2) addressing challenges with oral anticoagulants; and (3) delineating the optimal roles of percutaneous left atrial appendage occlusion and surgical left atrial appendage closure/excision. This report aims to promote innovative, impactful research that will lead to more personalized, effective use of stroke prevention strategies in people with AF.
Indexed as
Atrial FibrillationStrokeAcademies and InstitutesAgedHeartHumansNational Heart, Lung, and Blood Institute (U.S.)United Statesatrial fibrillationischemic strokepreventionrisk factorsstroke
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. · full record | OpenQuestion